These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 29544149)

  • 1. Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic leukemia.
    Wang Q; Liu F; Qi S; Qi Z; Yan XE; Wang B; Wang A; Wang W; Chen C; Liu X; Jiang Z; Hu Z; Wang L; Wang W; Ren T; Zhang S; Yun CH; Liu Q; Liu J
    Eur J Med Chem; 2018 Apr; 150():366-384. PubMed ID: 29544149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR associated drug resistant mutants in NSCLC.
    Chen Y; Wu J; Wang A; Qi Z; Jiang T; Chen C; Zou F; Hu C; Wang W; Wu H; Hu Z; Wang W; Wang B; Wang L; Ren T; Zhang S; Liu Q; Liu J
    Eur J Med Chem; 2017 Oct; 139():674-697. PubMed ID: 28850922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia.
    Liu X; Wang B; Chen C; Jiang Z; Hu C; Wu H; Zhang Y; Liu X; Wang W; Wang J; Hu Z; Wang A; Huang T; Liu Q; Wang W; Wang L; Wang W; Ren T; Li L; Xia R; Ge J; Liu Q; Liu J
    Eur J Med Chem; 2018 Dec; 160():61-81. PubMed ID: 30317026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia.
    Liang X; Liu X; Wang B; Zou F; Wang A; Qi S; Chen C; Zhao Z; Wang W; Qi Z; Lv F; Hu Z; Wang L; Zhang S; Liu Q; Liu J
    J Med Chem; 2016 Mar; 59(5):1984-2004. PubMed ID: 26789553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of 2,6,9-trisubstituted purines as potent PDGFRα kinase inhibitors with antileukaemic activity.
    Řezníčková E; Gucký T; Kováčová V; Ajani H; Jorda R; Kryštof V
    Eur J Med Chem; 2019 Nov; 182():111663. PubMed ID: 31514019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of 4-Methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((1-nicotinoylpiperidin-4-yl)oxy)benzamide (CHMFL-ABL/KIT-155) as a Novel Highly Potent Type II ABL/KIT Dual Kinase Inhibitor with a Distinct Hinge Binding.
    Wang Q; Liu F; Wang B; Zou F; Qi Z; Chen C; Yu K; Hu C; Qi S; Wang W; Hu Z; Liu J; Wang W; Wang L; Liang Q; Zhang S; Ren T; Liu Q; Liu J
    J Med Chem; 2017 Jan; 60(1):273-289. PubMed ID: 27966954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of S116836, a novel tyrosine kinase inhibitor, against imatinib-resistant FIP1L1-PDGFRα-expressing cells.
    Shen Y; Ren X; Ding K; Zhang Z; Wang D; Pan J
    Oncotarget; 2014 Nov; 5(21):10407-20. PubMed ID: 25431951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of (S)-2-amino-N-(5-(6-chloro-5-(3-methylphenylsulfonamido)pyridin-3-yl)-4-methylthiazol-2-yl)-3-methylbutanamide (CHMFL-PI3KD-317) as a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor.
    Liang X; Li F; Chen C; Jiang Z; Wang A; Liu X; Ge J; Hu Z; Yu K; Wang W; Zou F; Liu Q; Wang B; Wang L; Zhang S; Wang Y; Liu Q; Liu J
    Eur J Med Chem; 2018 Aug; 156():831-846. PubMed ID: 30053721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant.
    Lierman E; Folens C; Stover EH; Mentens N; Van Miegroet H; Scheers W; Boogaerts M; Vandenberghe P; Marynen P; Cools J
    Blood; 2006 Aug; 108(4):1374-6. PubMed ID: 16645167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML).
    Liu F; Wang B; Wang Q; Qi Z; Chen C; Kong LL; Chen JY; Liu X; Wang A; Hu C; Wang W; Wang H; Wu F; Ruan Y; Qi S; Liu J; Zou F; Hu Z; Wang W; Wang L; Zhang S; Yun CH; Zhai Z; Liu J; Liu Q
    Oncotarget; 2016 Jul; 7(29):45562-45574. PubMed ID: 27322145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of N-(3-(5-((3-acrylamido-4-(morpholine-4-carbonyl)phenyl)amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-methylphenyl)-4-(tert-butyl)benzamide (CHMFL-BTK-01) as a highly selective irreversible Bruton's tyrosine kinase (BTK) inhibitor.
    Liang Q; Chen Y; Yu K; Chen C; Zhang S; Wang A; Wang W; Wu H; Liu X; Wang B; Wang L; Hu Z; Wang W; Ren T; Zhang S; Liu Q; Yun CH; Liu J
    Eur J Med Chem; 2017 May; 131():107-125. PubMed ID: 28315597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trisubstituted purine inhibitors of PDGFRα and their antileukemic activity in the human eosinophilic cell line EOL-1.
    Malínková V; Řezníčková E; Jorda R; Gucký T; Kryštof V
    Bioorg Med Chem; 2017 Dec; 25(24):6523-6535. PubMed ID: 29089259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tri- and Tetrasubstituted Pyridinylimidazoles as Covalent Inhibitors of c-Jun N-Terminal Kinase 3.
    Muth F; El-Gokha A; Ansideri F; Eitel M; Döring E; Sievers-Engler A; Lange A; Boeckler FM; Lämmerhofer M; Koch P; Laufer SA
    J Med Chem; 2017 Jan; 60(2):594-607. PubMed ID: 27977190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ponatinib efficiently kills imatinib-resistant chronic eosinophilic leukemia cells harboring gatekeeper mutant T674I FIP1L1-PDGFRα: roles of Mcl-1 and β-catenin.
    Jin Y; Ding K; Li H; Xue M; Shi X; Wang C; Pan J
    Mol Cancer; 2014 Jan; 13():17. PubMed ID: 24472312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome.
    Griffin JH; Leung J; Bruner RJ; Caligiuri MA; Briesewitz R
    Proc Natl Acad Sci U S A; 2003 Jun; 100(13):7830-5. PubMed ID: 12808148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of 2-((3-Acrylamido-4-methylphenyl)amino)-N-(2-methyl-5-(3,4,5-trimethoxybenzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-BMX-078) as a Highly Potent and Selective Type II Irreversible Bone Marrow Kinase in the X Chromosome (BMX) Kinase Inhibitor.
    Liang X; Lv F; Wang B; Yu K; Wu H; Qi Z; Jiang Z; Chen C; Wang A; Miao W; Wang W; Hu Z; Liu J; Liu X; Zhao Z; Wang L; Zhang S; Ye Z; Wang C; Ren T; Wang Y; Liu Q; Liu J
    J Med Chem; 2017 Mar; 60(5):1793-1816. PubMed ID: 28140585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and synthesis of novel 2-phenylaminopyrimidine (PAP) derivatives and their antiproliferative effects in human chronic myeloid leukemia cells.
    Chang S; Yin SL; Wang J; Jing YK; Dong JH
    Molecules; 2009 Oct; 14(10):4166-79. PubMed ID: 19924055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of Potent, Selective Stem Cell Factor Receptor/Platelet Derived Growth Factor Receptor Alpha (c-KIT/PDGFRα) Dual Inhibitor for the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs).
    Lu Y; Mao F; Li X; Zheng X; Wang M; Xu Q; Zhu J; Li J
    J Med Chem; 2017 Jun; 60(12):5099-5119. PubMed ID: 28541695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants.
    Weisberg E; Choi HG; Ray A; Barrett R; Zhang J; Sim T; Zhou W; Seeliger M; Cameron M; Azam M; Fletcher JA; Debiec-Rychter M; Mayeda M; Moreno D; Kung AL; Janne PA; Khosravi-Far R; Melo JV; Manley PW; Adamia S; Wu C; Gray N; Griffin JD
    Blood; 2010 May; 115(21):4206-16. PubMed ID: 20299508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and synthesis of 4-(2,3-dihydro-1H-benzo[d]pyrrolo[1,2-a]imidazol-7-yl)-N-(5-(piperazin-1-ylmethyl)pyridine-2-yl)pyrimidin-2-amine as a highly potent and selective cyclin-dependent kinases 4 and 6 inhibitors and the discovery of structure-activity relationships.
    Wang Y; Liu WJ; Yin L; Li H; Chen ZH; Zhu DX; Song XQ; Cheng ZZ; Song P; Wang Z; Li ZG
    Bioorg Med Chem Lett; 2018 Mar; 28(5):974-978. PubMed ID: 29429832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.